Xiaobin Wu Sells 51,921 Shares of Beigene, Ltd. (NASDAQ:ONC) Stock

Beigene, Ltd. (NASDAQ:ONC) COO Xiaobin Wu sold 51,921 shares of Beigene stock in a transaction that occurred on Tuesday, April 1st. The shares were sold at an average price of $281.40, for a total transaction of $14,610,569.40. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.

Xiaobin Wu also recently made the following trade(s):

• On Wednesday, March 5th, Xiaobin Wu sold 51,921 shares of Beigene stock. The stock was sold at an average price of $261.59, for a total value of $13,582,014.39.
• On Thursday, February 20th, Xiaobin Wu sold 21,267 shares of Beigene stock. The stock was sold at an average price of $240.07, for a total value of $5,105,568.69.
• On Tuesday, February 18th, Xiaobin Wu sold 30,654 shares of Beigene stock. The shares were sold at an average price of $240.74, for a total transaction of $7,379,643.96.

Beigene Stock Down 9.8 %

Shares of ONC opened at $238.51 on Friday. The firm has a market capitalization of $23.53 billion, a P/E ratio of -28.95, a PEG ratio of 7.73 and a beta of 0.65. The company has a debt-to-equity ratio of 0.05, a current ratio of 1.93 and a quick ratio of 1.72. Beigene, Ltd. has a one year low of $126.97 and a one year high of $287.88.

Beigene (NASDAQ:ONC) last released its quarterly earnings results on Thursday, February 27th. The company reported ($1.43) EPS for the quarter, missing the consensus estimate of ($0.88) by ($0.55). Beigene had a negative net margin of 25.94% and a negative return on equity of 25.12%. The business had revenue of $1.13 billion for the quarter, compared to analysts’ expectations of $1.09 billion. On average, research analysts predict that Beigene, Ltd. will post -5.82 EPS for the current year.

Wall Street Analysts Forecast Growth

ONC has been the subject of several analyst reports. JMP Securities set a $348.00 price target on shares of Beigene in a research report on Friday, February 28th. Macquarie boosted their price target on Beigene from $259.00 to $313.00 and gave the stock an “outperform” rating in a research note on Friday, February 28th. Guggenheim reaffirmed a “buy” rating on shares of Beigene in a research report on Friday, February 28th. Sanford C. Bernstein set a $259.00 target price on Beigene in a research report on Thursday, March 13th. Finally, Bank of America raised shares of Beigene from a “neutral” rating to a “buy” rating and raised their price target for the company from $207.00 to $320.00 in a report on Monday, March 3rd.

About Beigene

BeiGene Ltd. Is a global oncology company, which engages in providing pharmaceutical products. Its medicines include BRUKINSA, TEVIMBRA, and PARTRUVIX. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in George Town, KY.